Physician profile
Brian M Lee
NPI 1558457556
$76,524.41
in general payments reported to CMS, 2019-2025
19 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $5,819 · 2021: $8,021 · 2022: $16K · 2023: $8,371 · 2024: $8,733 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $4,900 · Food and Beverage: $2,660 · Travel and Lodging: $2,624 · Education: $25.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,425.00 |
| Consulting Fee | $4,900.00 |
| Food and Beverage | $2,659.84 |
| Travel and Lodging | $2,623.55 |
| Education | $25.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $34,699.96 | 2019-2023 | Krystexxa |
| Amgen INC. | $26,336.58 | 2020-2025 | Krystexxa, Tavneos, Parsabiv |
| Outset Medical INC | $10,498.16 | 2021-2024 | |
| Vifor Pharma, INC. | $2,827.52 | 2021-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $618.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.06 | 2021-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $318.19 | 2020-2022 | |
| Ardelyx, INC. | $183.11 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $121.71 | 2022 | |
| Akebia Therapeutics INC | $113.51 | 2023-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $86.23 | 2023-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $81.89 | 2023-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $81.23 | 2022-2025 | Jynarque |
| Boston Scientific Corporation | $78.84 | 2024 | |
| Fresenius USA Marketing, INC. | $43.09 | 2023-2024 | Velphoro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.30 | 2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.13 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $22.59 | 2023 | |
| Travere Therapeutics, INC. | $20.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.